跳至主要内容
临床试验/JPRN-UMIN000003772
JPRN-UMIN000003772已完成1 期

Continuous administration study of peptide-cocktail vaccination for HCV-positive patients with liver cancer who have undergone radical therapy. - Continuous administration study of peptid vaccination to prevent recurrence of HCV-positive liver cancer.

Kurume University Cancer Vaccine Center0 个研究点目标入组 3 人开始时间: 2010年6月21日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
3

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 81years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2)Patients with multiple active cancers 3)Patients suspected with immunodeficiency and opportunistic infection. 4) Patients with the past history of severe allergic reactions. 5)Patients who are during pregnancy, lactation expectant, and desiring future fertility. 6)Patients with a score II or more of hepatic encephalopathy. 7) Patients who are judged inappropriate for the clinical trial by doctors.

研究者

发起方
Kurume University Cancer Vaccine Center

相似试验